

## Appendix

Table A1: Results from sensitivity analysis. Fully-adjusted multinomial logistic regression analysis investigating the association between demographic and clinical factors with different antidepressant treatments.

	Any one SNRI and Mirtazapine	Any one SSRI and Mirtazapine	Any two SSRIs	Citalopram	Escitalopram	Fluoxetine	Mirtazapine	Venlafaxine
Age	<b>1.04 (1.03 – 1.06)</b>	<b>1.03 (1.02 – 1.04)</b>	<b>0.97 (0.96 – 0.99)</b>	<b>1.01 (1.00 – 1.02)</b>	1.01 (0.99 – 1.03)	<b>0.97 (0.96 – 0.98)</b>	<b>1.03 (1.02 – 1.04)</b>	<b>1.02 (1.01 – 1.04)</b>
Gender (a)	1.00 (0.60 – 1.67)	1.32 (0.83 – 2.08)	0.95 (0.56 – 1.61)	0.96 (0.66 – 1.40)	1.06 (0.58 – 2.00)	1.04 (0.71 – 1.54)	<b>2.62 (1.89 – 3.64)</b>	1.15 (0.76 – 1.75)
Race (White)	1.19 (0.71 – 2.01)	0.95 (0.60 – 1.51)	0.80 (0.50 – 1.30)	1.12 (0.78 – 1.61)	1.90 (0.98 – 3.74)	1.23 (0.85 – 1.78)	0.75 (0.54 – 1.04)	1.34 (0.87 – 2.06)
Past Inpatient: Yes (b)	1.13 (0.49 – 2.62)	1.24 (0.58 – 2.65)	0.97 (0.41 – 2.27)	0.90 (0.43 – 1.90)	0.60 (0.14 – 2.54)	0.47 (0.21 – 1.05)	0.71 (0.38 – 1.32)	0.70 (0.31 – 1.51)
Past Benzodiazepine Use: Yes (b)	1.39 (0.75 – 2.57)	1.04 (0.56 – 1.93)	1.63 (0.82 – 3.24)	1.57 (0.92 – 2.67)	1.78 (0.80 – 3.98)	0.88 (0.48 – 1.60)	<b>1.62 (1.04 – 2.55)</b>	1.68 (0.98 – 2.89)
Past Mood Stabiliser Use: Yes (b)	<b>2.61 (1.15 – 5.91)</b>	1.22 (0.47 – 3.17)	1.46 (0.50 – 4.30)	0.96 (0.39 – 2.35)	2.60 (0.93 – 7.21)	1.53 (0.65 – 3.60)	1.28 (0.62 – 2.63)	<b>3.08 (1.51 – 6.30)</b>
Past Antidepressant Use: Yes (b)	<b>3.70 (1.55 – 8.86)</b>	1.06 (0.59 – 1.93)	<b>0.54 (0.30 – 0.98)</b>	0.73 (0.48 – 1.12)	1.58 (0.72 – 3.46)	1.28 (0.81 – 2.02)	0.97 (0.63 – 1.48)	1.23 (0.72 – 2.12)
Has had Psychotherapy treatment before: Yes (b)	0.65 (0.31 – 1.37)	0.90 (0.47 – 1.71)	0.92 (0.44 – 1.94)	0.52 (0.28 – 1.01)	1.05 (0.43 – 2.57)	0.88 (0.50 – 1.58)	<b>0.56 (0.33 – 0.96)</b>	0.77 (0.41 – 1.42)
Has been referred to IAPT services: Yes (b)	<b>1.80 (1.09 – 2.98)</b>	0.98 (0.63 – 1.54)	0.81 (0.50 – 1.31)	0.95 (0.68 – 1.36)	1.10 (0.61 – 2.01)	<b>0.64 (0.45 – 0.93)</b>	0.87 (0.63 – 1.20)	0.75 (0.50 – 1.13)
Psychotic Symptom: $\geq 2$ mentions (c)	0.90 (0.45 – 1.81)	1.57 (0.85 – 2.91)	0.98 (0.49 – 1.96)	1.54 (0.90 – 2.65)	0.73 (0.27 – 2.02)	1.39 (0.80 – 2.40)	1.20 (0.75 – 1.87)	1.24 (0.70 – 2.22)
Cognitive Symptom: $\geq 2$ mentions (c)	1.35 (0.70 – 2.63)	1.38 (0.73 – 2.61)	1.17 (0.58 – 2.37)	0.95 (0.52 – 1.72)	0.95 (0.35 – 2.56)	0.80 (0.42 – 1.49)	0.71 (0.43 – 1.17)	1.32 (0.73 – 2.40)
Affective Symptom: $\geq 2$ mentions (c)	0.54 (0.28 – 1.04)	0.60 (0.32 – 1.12)	0.93 (0.47 – 1.83)	<b>0.58 (0.36 – 0.92)</b>	0.70 (0.33 – 1.51)	<b>0.42 (0.25 – 0.68)</b>	0.80 (0.51 – 1.25)	0.92 (0.54 – 1.56)
Somatic Symptom: $\geq 2$ mentions (c)	1.42 (0.74 – 2.71)	1.02 (0.55 – 1.90)	0.90 (0.47 – 1.75)	0.66 (0.40 – 1.09)	0.88 (0.40 – 1.96)	1.09 (0.66 – 1.81)	<b>1.60 (1.04 – 2.46)</b>	0.71 (0.42 – 1.22)
Past Suicide Ideation: Yes (b)	1.40 (0.79 – 2.47)	1.11 (0.64 – 1.91)	1.03 (0.57 – 1.86)	0.80 (0.50 – 1.29)	0.80 (0.36 – 1.79)	0.84 (0.53 – 1.35)	0.91 (0.61 – 1.37)	0.82 (0.49 – 1.38)
Past Suicide Attempt: Yes (b)	0.94 (0.49 – 1.83)	1.46 (0.81 – 2.61)	1.79 (0.97 – 3.29)	1.26 (0.76 – 2.08)	0.62 (0.23 – 1.64)	1.56 (0.97 – 2.52)	1.11 (0.71 – 1.74)	1.12 (0.65 – 1.95)

p-value: ‡ < 0.05; †† < 0.001

a – Reference: Female

b – Reference: No

c – Reference: 0 or 1 mention of the symptom. Individuals with zero or one mention of a symptom in the 12-month period prior to the observation frame were considered to be undergoing a milder experience of the symptom compared to individuals who had two or more mentions of the symptom in the 12-month period.

Table A2: Results from sensitivity analysis. Fully-adjusted multinomial logistic regression analysis investigating the association between demographic and clinical factors with different antidepressant treatments in the adult-only cohort (n = 1248).

	Any one SNRI and Mirtazapine	Any one SSRI and Mirtazapine	Any two SSRIs	Citalopram	Escitalopram	Fluoxetine	Mirtazapine	Venlafaxine
Age	<b>1.04 (1.02 – 1.05)</b>	<b>1.03 (1.01 – 1.05)</b>	0.99 (0.97 – 1.02)	1.00 (0.99 – 1.02)	1.00 (0.99 – 1.03)	0.99 (0.98 – 1.01)	<b>1.03 (1.01 – 1.04)</b>	<b>1.02 (1.01 – 1.04)</b>
Gender (a)	0.88 (0.51 – 1.50)	1.28 (0.79 – 2.08)	0.89 (0.47 – 1.70)	0.90 (0.50 – 1.36)	1.02 (0.52 – 2.01)	1.24 (0.78 – 2.00)	<b>2.33 (1.63 – 3.34)</b>	1.08 (0.69 – 1.70)
Past Inpatient: Yes (b)	1.08 (0.44 – 2.62)	0.96 (0.41 – 2.21)	0.30 (0.07 – 1.26)	0.79 (0.34 – 1.83)	0.58 (0.10 – 3.22)	0.51 (0.19 – 1.37)	0.60 (0.30 – 1.20)	0.59 (0.25 – 1.40)
Past Benzodiazepine Use: Yes (b)	1.44 (0.76 – 2.75)	1.26 (0.66 – 2.43)	<b>2.89 (1.30 – 6.43)</b>	1.56 (0.87 – 2.80)	1.85 (0.79 – 4.35)	1.14 (0.58 – 2.25)	<b>1.92 (1.18 – 3.12)</b>	<b>1.87 (1.04 – 3.33)</b>
Past Antipsychotic Use: Yes (b)	<b>2.01 (1.14 – 3.55)</b>	1.30 (0.73 – 2.27)	1.03 (0.47 – 2.27)	1.09 (0.66 – 1.81)	1.67 (0.80 – 3.52)	1.01 (0.57 – 1.80)	1.14 (0.74 – 1.75)	1.50 (0.90 – 2.50)
Past Mood Stabiliser Use: Yes (b)	2.25 (0.96 – 5.26)	1.02 (0.36 – 2.86)	1.11 (0.30 – 4.22)	0.77 (0.28 – 2.10)	2.52 (0.87 – 7.29)	1.71 (0.67 – 4.35)	1.24 (0.58 – 2.64)	<b>2.65 (1.23 – 5.70)</b>
Past Antidepressant Use: Yes (b)	<b>2.76 (1.12 – 6.81)</b>	0.92 (0.48 – 1.78)	<b>0.40 (0.19 – 0.85)</b>	0.70 (0.42 – 1.13)	2.19 (0.85 – 5.67)	1.04 (0.59 – 1.86)	0.80 (0.50 – 1.30)	1.08 (0.59 – 2.00)
Has been referred to IAPT services: Yes (b)	<b>2.04 (1.20 – 3.47)</b>	0.97 (0.60 – 1.59)	0.91 (0.50 – 1.69)	0.98 (0.66 – 0.47)	1.34 (0.68 – 2.60)	0.97 (0.61 – 1.53)	0.93 (0.64 – 1.34)	0.82 (0.52 – 1.28)
Psychotic Symptom: >=2 mentions (c)	0.80 (0.38 – 1.67)	1.70 (0.87 – 3.31)	0.89 (0.34 – 2.21)	1.67 (0.92 – 3.03)	0.72 (0.23 – 2.18)	1.45 (0.75 – 2.81)	1.22 (0.74 – 2.03)	1.18 (0.63 – 2.21)
Cognitive Symptom: >=2 mentions (c)	1.14 (0.57 – 2.30)	1.28 (0.65 – 2.56)	0.89 (0.35 – 2.25)	0.84 (0.43 – 1.62)	0.99 (0.34 – 2.88)	0.78 (0.37 – 1.64)	0.60 (0.35 – 1.02)	1.11 (0.58 – 2.11)
Affective Symptom: >=2 mentions (c)	0.51 (0.25 – 1.01)	0.59 (0.30 – 1.14)	0.92 (0.41 – 2.08)	<b>0.49 (0.29 – 0.82)</b>	0.51 (0.23 – 1.15)	<b>0.36 (0.20 – 0.67)</b>	0.79 (0.53 – 1.28)	0.93 (0.53 – 1.66)
Somatic Symptom: >=2 mentions (c)	1.40 (0.72 – 2.75)	0.99 (0.52 – 1.92)	1.11 (0.50 – 2.50)	0.66 (0.38 – 1.16)	1.00 (0.42 – 2.36)	1.17 (0.63 – 2.18)	<b>1.63 (1.02 – 2.59)</b>	0.69 (0.40 – 1.22)
Past Suicide Ideation: Yes (b)	1.37 (0.76 – 2.48)	1.08 (0.60 – 1.95)	0.89 (0.40 – 1.98)	0.79 (0.47 – 1.35)	0.53 (0.20 – 1.39)	0.92 (0.51 – 1.67)	0.92 (0.60 – 1.44)	0.84 (0.50 – 1.48)
Past Suicide Attempt: Yes (b)	1.03 (0.51 – 2.09)	1.44 (0.76 – 2.77)	1.75 (0.77 – 4.00)	1.45 (0.81 – 2.58)	0.44 (0.12 – 1.62)	<b>2.06 (1.11 – 3.84)</b>	1.18 (0.72 – 1.95)	1.17 (0.64 – 2.16)

p-value: ‡ <0.05; †† < 0.001

a – Reference: Female

b – Reference: No

c – Reference: 0 or 1 mention of the symptom. Individuals with zero or one mention of a symptom in the 12-month period prior to the observation frame were considered to be undergoing a milder experience of the symptom compared to individuals who had two or more mentions of the symptom in the 12-month period.